The Most Trusted Name in Cannabis
Tikun Olam is an international cannabis wellness brand sold in Israel, Canada, Australia, South Africa and the U.S. reaching tens of thousands of patients worldwide. We are dedicated to improving the quality of life of our patients and providing them with strains and products they can trust. Our ongoing commitment to wellness means we only cultivate premium quality cannabis in the lab, in the field, and in concert with our business partners. We genuinely care about patients and believe they should be able to rely on the quality and consistency of their medical cannabis.
Building on a history of medical cannabis research in Israel, Tzachi Cohen founded a non-profit organization called, Tikun Olam to deliver safe and consistent cannabis medicine to patients. Tikun Olam became the first provider of medical cannabis in 2005 and then made history as the first company to receive a government-issued license to supply cannabis in Israel, in 2007. Tikun has worked with hospitals, nursing homes, and co-ops to distribute our medical-grade cannabis for over a decade. During this time, under the observation of certified nurses who ensure personalized treatment plans and appropriate medicine delivery methods, we collected the data that now forms the world’s largest medical cannabis treatment database containing more than 17,000 patient records including their conditions, symptoms, strain usage, dosage and associated levels of relief and improvement in quality of life, over the years. We work with a variety of patients including the elderly and children, with conditions as HIV/AIDS, PTSD, epilepsy, chronic pain, cancer, Colitis or Crohn’s disease, depression, anxiety and much more.
Tikun Olam is proud to be on the cutting edge of medical cannabis research. We are continually examining the effects our strains and products have in the treatment and management of specific symptoms and diseases through data collection and studies. We have participated in multiple trials and studies all yielding positive outcomes including significant healing for patients and improved quality life.
Tikun was the first company to innovate and breed a high CBD low THC strain, “Avidekel,” which has been recognized internationally and dubbed the first “highless” marijuana strain by Reuters in 2012. We conducted the world’s first and only successful Phase II clinical double blind study using cannabis as treatment for Crohn’s Disease and Colitis. Both studies showed a significant increase in quality of life for patients, a reduction in medication use and dramatic improvement in symptoms. Avidekel has been used to successfully treat over 200 children with drug resistant epilepsy and neurological disorders with significant reduction of symptoms for all patients. Our ongoing R&D allows us to breed strains and tailor their genetic profiles in order to enhance their range of effects.
Tikun Olam draws on the knowledge of several of Israel’s top experts in research, cultivation, operations, and product development, including our own head of research, Professor Zvi Bentwich, who is a leading researcher in cannabis use for HIV/AIDS internationally, and Rafael Mechoulam, the "father of cannabis research." We continue to collaborate with various researchers, scientists, and top universities and hospitals participating in and contributing to medical studies of cannabis use, effects, and therapeutic benefits.
With over a decade of scientific research, the world’s largest medical cannabis patient database and a commitment to the health and wellness of patients, Tikun is an authentic brand you can trust.